Eutilex is a biotechnology company focused on the research and development of three in-house immunotherapeutic platforms such as innovative Eutilex T cell therapy, chimeric antigen receptor (CAR) T therapy and immune-oncology antibody therapies to strive against incurable diseases such as cancers. Eutilex was founded in 2015, Seoul, South Korea and achieved IPO at the end of 2018.
Eutilex’s CEO, Byoung S. Kwon, has been a leading immuno-oncology researcher for 40 years and one of the main achievements he made is discovery of human 4-1BB, an inducible costimulatory receptor expressed on activated T cells, which becomes the foundations of the three in-house immunotherapeutic platforms.
Utilizing its knowledge-based COSTIM (costimulatory) platform technology, Eutilex has developed more than 15 monoclonal and bispecific immune-oncology antibodies.
Eutilex is also developing malignancy variant receptor (MVR) CAR-T that is a novel target, human leukocyte antigen-DR (HLA-DR). One of the key differentiators from CD19 CAR-T is that HLA-DR is minimally expressed on normal B cells but overexpressed on malignant B cells, attacking specifically B cell lymphoma, not normal B cell.
The mission of Eutilex is to dedicate to develop and deliver innovative immune-oncology therapeutics to patients in desperate need and return Eutilex’s benefit to society.
State of Ownership